These early non-responders often exit programs within the first few weeks, citing failure to achieve the expected goal and expressing feelings of frustration and disappointment
Since these medications require careful storage and regular injection, its important to plan ahead to ensure you can continue your treatment while traveling
Recent developments: April 2026, The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially limiting large-scale compounding activities
When selecting a supplier, prioritize those offering certificates of analysis, HPLC purity verification (95%+), and proper cold-chain shipping to maintain peptide integrity
While still under investigation, these findings highlight GLP1-Ss broader research potential beyond glycemic control alone
Get in touch with us by calling our patient enquiry team or using your companion app